Actively Recruiting
A Clinical Study of T3011 in Subjects With Advanced Melanoma
Led by Shanghai Pharmaceuticals Holding Co., Ltd · Updated on 2026-01-14
42
Participants Needed
7
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.
CONDITIONS
Official Title
A Clinical Study of T3011 in Subjects With Advanced Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have advanced melanoma
- Have at least one measurable tumor lesion
- Have an ECOG performance status of 0 or 1
- Expected survival longer than 12 weeks
- Meet laboratory test requirements
- For women who can become pregnant, have a negative pregnancy test within 7 days before first dose and agree to use effective contraception until 6 months after last dose
- For men who can father children, agree to use effective contraception and not donate sperm from consent until 6 months after last dose
- Understand and voluntarily sign informed consent and agree to comply with study requirements
You will not qualify if you...
- Received other antitumor therapy within the specified time before first dose
- History of other cancers within the specified time before study treatment
- History or signs of high-risk cardiovascular disease at screening
- Active infection requiring intravenous antibiotics
- Autoimmune diseases or history of autoimmune diseases
- Known psychiatric disorders affecting compliance
- Pleural, pericardial effusion, or ascites needing drainage before treatment or recent drainage
- Need for systemic treatment with anti-HSV drugs during study
- Received live or attenuated vaccines recently or plan to during study
- Received any tumor vaccine in the past
- Major surgery within specified time before first dose without recovery or planning major surgery during study
- History of drug, alcohol abuse within 1 year before consent
- Pregnant, breastfeeding, or planning pregnancy during study
- Investigator considers participation inappropriate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Beijing Cancer Hospital
Beijing, China
Actively Recruiting
2
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Actively Recruiting
3
Jilin Cancer Hospital
Changchun, China
Actively Recruiting
4
Chengdu Shangjin Nanfu Hospital
Chengdu, China
Actively Recruiting
5
Fujian Cancer Hospital
Fuzhou, China
Actively Recruiting
6
The Third People's Hospital of Zhengzhou
Zhengzhou, China
Actively Recruiting
7
Sun Yat-sen University Cancer Center
Zhongshan, China
Actively Recruiting
Research Team
J
Jun Guo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here